Clinical Trial

Rabies mAb CBB 1 Combination Vaccine in Healthy People With Antibody Neutralization Activity and Safety Phase Clinical Trials

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 12, 2024 (before its estimated May 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the antibody neutralization activity and safety of rabies mAb CBB 1 combination vaccine used in healthy people
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06548139
Lead Sponsor Changchun BCHT Biotechnology Co.
Collaborators: The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine, Anning City First People's Hospital, Yunnan Central Hospital, Beijing Contreke Statistical Technology Co., LTD, Military Science Zhengyuan (Beijing) Pharmaceutical Research Co., LTD
Conditions Rabies Virus Infection
Enrollment 120 participants
Start Date 2024-07-31
Primary Completion 2025-05-31 (estimated)
Study Completion 2025-05-31 (estimated)
Updated on ClinicalTrials.gov 2024-08-12